{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:44:08Z","timestamp":1761561848131},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12325-014-0110-3","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T12:25:27Z","timestamp":1394108727000},"page":"410-425","source":"Crossref","is-referenced-by-count":18,"title":["Treatment Patterns Following Discontinuation of Adalimumab, Etanercept, and Infliximab in a US Managed Care Sample"],"prefix":"10.1007","volume":"31","author":[{"given":"Jason","family":"Yeaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vernon F.","family":"Schabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,7]]},"reference":[{"key":"110_CR1","unstructured":"Bathon J. Anti-TNF therapy for the treatment of rheumatoid arthritis. Johns Hopkins Arthritis Center, Baltimore, MD. 2011. http:\/\/www.hopkinsarthritis.org\/arthritis-info\/rheumatoid-arthritis\/ . Date Accessed 22 Aug 2013."},{"key":"110_CR2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3111\/13696998.2011.644645","volume":"15","author":"VF Schabert","year":"2012","unstructured":"Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15:264\u201375.","journal-title":"J Med Econ"},{"key":"110_CR3","unstructured":"Enbrel\u00ae (etanercept) Prescribing Information, Immunex Corporation, Thousand Oaks, CA. 2013."},{"key":"110_CR4","unstructured":"Humira\u00ae (adalimumab) Prescribing Information, Abbott Laboratories, Abbott Park, IL. 2013."},{"key":"110_CR5","unstructured":"Remicade\u00ae (infliximab) Prescribing Information, Centocor, Inc., Malvern, PA. 2013."},{"key":"110_CR6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22\u201332.","journal-title":"Arthritis Rheum"},{"key":"110_CR7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/ard.2007.083675","volume":"67","author":"W Kievit","year":"2008","unstructured":"Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67:1229\u201334.","journal-title":"Ann Rheum Dis"},{"key":"110_CR8","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar2084","volume":"8","author":"LE Kristensen","year":"2006","unstructured":"Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.","journal-title":"Arthritis Res Ther"},{"key":"110_CR9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Pan Du","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560\u20138.","journal-title":"Arthritis Rheum"},{"key":"110_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234\u201340.","journal-title":"Arthritis Rheum"},{"key":"110_CR11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837\u201346.","journal-title":"Ann N Y Acad Sci"},{"key":"110_CR12","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","volume":"68","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856\u201362.","journal-title":"Ann Rheum Dis"},{"key":"110_CR13","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.","journal-title":"Arthritis Res Ther"},{"key":"110_CR14","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.","journal-title":"Arthritis Res Ther"},{"key":"110_CR15","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.","journal-title":"Arthritis Res Ther"},{"key":"110_CR16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","volume":"46","author":"American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines","year":"2002","unstructured":"American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328\u201346.","journal-title":"Arthritis Rheum"},{"key":"110_CR17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762\u201384.","journal-title":"Arthritis Rheum"},{"key":"110_CR18","unstructured":"Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. National Institute for Health and Care Excellence, London. 2007. http:\/\/www.nice.org.uk\/TA130 . Accessed 23 Aug 2013."},{"key":"110_CR19","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3899\/jrheum.090054","volume":"36","author":"M Blom","year":"2009","unstructured":"Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36:2171\u20137.","journal-title":"J Rheumatol"},{"key":"110_CR20","first-page":"2356","volume":"31","author":"B Haraoui","year":"2004","unstructured":"Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol. 2004;31:2356\u20139.","journal-title":"J Rheumatol"},{"key":"110_CR21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","volume":"46","author":"S Bombardieri","year":"2007","unstructured":"Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford). 2007;46:1191\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"110_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13\u201320.","journal-title":"Arthritis Rheum"},{"key":"110_CR23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.clinthera.2009.04.002","volume":"31","author":"DA Ollendorf","year":"2009","unstructured":"Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31:825\u201335.","journal-title":"Clin Ther"},{"key":"110_CR24","first-page":"313","volume":"17","author":"BJ Wong","year":"2011","unstructured":"Wong BJ, Cifaldi MA, Roy S, Skonieczny DC, Stavrakas S. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. J Manag Care Pharm. 2011;17:313\u201320.","journal-title":"J Manag Care Pharm"},{"key":"110_CR25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.18553\/jmcp.2013.19.8.621","volume":"19","author":"VF Schabert","year":"2013","unstructured":"Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19:621\u201330.","journal-title":"J Manag Care Pharm"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0110-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-014-0110-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0110-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T21:31:24Z","timestamp":1648503084000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0110-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0110-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,7]]}}}